Biomarkers in acute heart failure.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Revista Española de Cardiología

• Publication date

  2015-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.rec.2015.02.009PMID 25911167
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison between admission natriuretic peptides, NGAL and sST2 testing for the prediction of worsening renal function in patients with acutely decompensated heart failure

  2015cited by this paper
• Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

  2015cited by this paper
• High-Sensitivity Troponin T: A Biomarker for Diuretic Response in Decompensated Heart Failure Patients

  2014cited by this paper
• Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study).

  2014cited by this paper
• Novel biomarkers in acute heart failure: MR-pro-adrenomedullin

  2014cited by this paper
• Prognostic Value of Plasma Neutrophil Gelatinase–Associated Lipocalin for Mortality in Patients With Heart Failure

  2014cited by this paper
• Comprehensive Review of the Prognostic Value of Galectin-3 in Heart Failure

  2014cited by this paper
• Excluding infection through procalcitonin testing improves outcomes of congestive heart failure patients presenting with acute respiratory symptoms: results from the randomized ProHOSP trial.

  2014cited by this paper
• When Cardiac Failure, Kidney Dysfunction, and Kidney Injury Intersect in Acute Conditions: The Case of Cardiorenal Syndrome

  2014cited by this paper
• Usefulness of Combining Galectin-3 and BIVA Assessments in Predicting Short- and Long-Term Events in Patients Admitted for Acute Heart Failure

  2014cited by this paper
• Angiotensin-neprilysin inhibition versus enalapril in heart failure.

  2014cited by this paper
• Procalcitonin testing for diagnosis and short-term prognosis in bacterial infection complicated by congestive heart failure: a multicenter analysis of 4,698 cases

  2014cited by this paper
• Evidence of Uncoupling between Renal Dysfunction and Injury in Cardiorenal Syndrome: Insights from the BIONICS Study

  2014cited by this paper
• Prognostic value of high sensitivity troponin T in patients with acutely decompensated heart failure and non-detectable conventional troponin T levels.

  2013cited by this paper
• A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: ÉLAN-HF Score

  2013cited by this paper
• Soluble Concentrations of the Interleukin Receptor Family Member ST2 and &bgr;-Blocker Therapy in Chronic Heart Failure

  2013cited by this paper
• Soluble ST2 predicts elevated SBP in the community

  2013cited by this paper
• Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes.

  2013cited by this paper
• Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction.

  2013cited by this paper
• Surfing the biomarker tsunami at JACC: heart failure.

  2013cited by this paper
• 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2013cited by this paper
• Heart failure therapy-induced early ST2 changes may offer long-term therapy guidance.

  2013cited by this paper
• 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

  2013cited by this paper
• Comparison of risk prediction with the CKD-EPI and MDRD equations in acute decompensated heart failure.

  2013cited by this paper
• Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study.

  2013influential reference
• Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea.

  2012cited by this paper
• Relationship of Plasma Galectin-3 to Renal Function in Patients With Heart Failure: Effects of Clinical Status, Pathophysiology of Heart Failure, and Presence or Absence of Heart Failure

  2012cited by this paper
• Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial

  2012influential reference
• Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study.

  2012cited by this paper
• Emerging biomarkers in heart failure.

  2012cited by this paper
• Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section.

  2012cited by this paper
• Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy

  2012cited by this paper
• Serial Monitoring of Soluble Interleukin Family Member ST2 in Patients with Acutely Decompensated Heart Failure

  2012cited by this paper
• Biomarkers in acute heart failure—state of the art

  2012cited by this paper
• Natriuretic peptide testing for predicting adverse events following heart failure hospitalization.

  2012cited by this paper
• Galectin 3 complements BNP in risk stratification in acute heart failure

  2012cited by this paper
• Highly sensitive troponin T for risk stratification of acutely destabilized heart failure.

  2012cited by this paper
• ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012

  2012cited by this paper
• Biomarker changes during acute heart failure treatment.

  2012cited by this paper
• Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: The NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial

  2011cited by this paper
• Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.

  2011cited by this paper
• β-trace protein and cystatin C as predictors of long-term outcomes in patients with acute heart failure.

  2011cited by this paper
• Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart.

  2011cited by this paper
• Serial changes in high‐sensitive troponin I predict outcome in patients with decompensated heart failure

  2011cited by this paper
• Soluble ST2, high‐sensitivity troponin T‐ and N‐terminal pro‐B‐type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure

  2011cited by this paper
• Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction.

  2011cited by this paper
• HFSA 2010 Comprehensive Heart Failure Practice Guideline.

  2010cited by this paper
• The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI‐heart failure (GISSI‐HF) trial

  2010cited by this paper
• Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.

  2010cited by this paper
• Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate

  2010cited by this paper
• Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure.

  2010cited by this paper
• Galectin‐3, cardiac structure and function, and long‐term mortality in patients with acutely decompensated heart failure

  2010cited by this paper
• Improving the diagnosis of acute heart failure using a validated prediction model.

  2009cited by this paper
• Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma--the Presage ST2 assay.

  2009influential reference
• Natriuretic peptide-guided management of acutely destabilized heart failure: rationale and treatment algorithm.

  2009cited by this paper
• Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects.

  2009cited by this paper
• Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE (Acute Decompensated Heart Failure National Registry) analysis.

  2008cited by this paper
• Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure.

  2008cited by this paper
• Importance and interpretation of intermediate (gray zone) amino-terminal pro-B-type natriuretic peptide concentrations.

  2008cited by this paper
• Independent and incremental prognostic value of multimarker testing in acute dyspnea: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study.

  2008cited by this paper
• Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure.

  2008cited by this paper
• Clinical uncertainty, diagnostic accuracy, and outcomes in emergency department patients presenting with dyspnea.

  2008cited by this paper
• The differential diagnosis of an elevated amino-terminal pro-B-type natriuretic peptide level.

  2008cited by this paper
• ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: application of natriuretic peptides.

  2008cited by this paper
• N-Terminal Pro–B-Type Natriuretic Peptide Testing Improves the Management of Patients With Suspected Acute Heart Failure: Primary Results of the Canadian Prospective Randomized Multicenter IMPROVE-CHF Study

  2007cited by this paper
• Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study.

  2007cited by this paper
• Evidence for functional heterogeneity of circulating B-type natriuretic peptide.

  2007cited by this paper
• Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea.

  2007cited by this paper
• NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study.

  2006cited by this paper
• Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure.

  2006cited by this paper
• Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea.

  2006cited by this paper
• Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department.

  2006cited by this paper
• Amino-terminal pro-brain natriuretic Peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction?

  2006cited by this paper
• Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure.

  2005influential reference
• Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis.

  2005cited by this paper
• The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study.

  2005cited by this paper
• Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy.

  2005cited by this paper
• Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction

  2004cited by this paper
• Prognostic Role of Brain Natriuretic Peptide in Acute Pulmonary Embolism

  2003cited by this paper
• Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study.

  2003cited by this paper
• Expression and Regulation of ST2, an Interleukin-1 Receptor Family Member, in Cardiomyocytes and Myocardial Infarction

  2002cited by this paper
• Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction.

  2002cited by this paper
• Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.

  2002cited by this paper
• Increase in plasma adrenomedullin in patients with heart failure characterised by diastolic dysfunction

  2001cited by this paper
• Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure.

  2000cited by this paper
• Increased plasma levels of adrenomedullin in patients with heart failure.

  1995cited by this paper
• Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching.

  1993cited by this paper
• Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide.

  1991cited by this paper

• Galectins and Liver Diseases

  2025cites this paper
• Assessment of Decongestion Status Before Discharge in Acute Decompensated Heart Failure: A Review of Clinical, Biochemical, and Imaging Tools and Their Impact on Management Decisions

  2025cites this paper
• Can Endothelin-1 Help Address the Diagnostic and Prognostic Challenges in Multimorbid Acute Heart Failure Patients?

  2025cites this paper
• The Role and Implications of COVID-19 in Incident and Prevalent Heart Failure

  2024cites this paper
• DETERMINATION OF THE DYNAMICS OF NATRIURETIC PEPTIDE IN RESPONSE TO VOLUME LOAD IN PATIENTS WITH ACUTE SURGICAL PATHOLOGY OF THE ABDOMINAL CAVITY

  2024cites this paper
• Rehabilitation training effect guided by cardiopulmonary fitness assessment on NT-proBNP levels in patients with chronic heart failure.

  2024cites this paper
• Role of Biomarkers in Critical Care Medicine: A Review

  2024cites this paper
• Biomarkers as Prognostic Predictors and Therapeutic Guide in Critically Ill Patients: Clinical Evidence

  2023cites this paper
• Developing a Preliminary Clinical Prediction Model for Prognosis of Pneumonia Complicated with Heart Failure Based on Metagenomic Sequencing

  2023cites this paper
• Could Endothelin-1 Be a Promising Neurohormonal Biomarker in Acute Heart Failure?

  2023cites this paper
• Approaches and Challenges for Biosensors for Acute and Chronic Heart Failure

  2023cites this paper
• New Opportunities in Heart Failure with Preserved Ejection Fraction: From Bench to Bedside… and Back

  2022cites this paper
• Huangqi Shengmai Yin Ameliorates Myocardial Fibrosis by Activating Sirtuin3 and Inhibiting TGF-β/Smad Pathway

  2021cites this paper
• PGPM_A_323379 1169..1184

  2021cites this paper
• Biomarkers in the management of acute heart failure: state of the art and role in COVID‐19 era

  2021influential citation
• Valore prognostico dei biomarcatori nel predire la mortalità cardiovascolare in una coorte di anziani istituzionalizzati

  2021cites this paper
• Metabolic Processes are Potential Biological Processes Distinguishing Nonischemic Dilated Cardiomyopathy from Ischemic Cardiomyopathy: A Clue from Serum Proteomics

  2021cites this paper
• Blood Biomarker Panels for the Early Prediction of Stroke‐Associated Complications

  2021cites this paper
• Serum Adropin and Apelin as Potential Markers PredictingAcute Heart Failure-associated Renal Dysfunction among Elderly Iraqi Patients

  2020cites this paper
• NT-proBNP as a Predictor of Left Ventricular Systolic Dysfunction After Coronary Artery Bypass Grafting

  2020cites this paper
• Changes on Serum Troponin T Level before and after Taking Standard Therapy Medication in Heart Failure Patients

  2020cites this paper
• Prediction of all-cause mortality with hypoalbuminemia in patients with heart failure: a meta-analysis

  2019cites this paper
• Proadrenomedullin determining clinical severity and analyzing prognostic value for pneumonia

  2019cites this paper
• Cystatin C for predicting all-cause mortality and rehospitalization in patients with heart failure: a meta-analysis

  2019cites this paper
• FORECAST OF PATIENTS WITH ACUTE MYOCARDIAL INFARCTION AT THE STATE TREATMENT STATION

  2019cites this paper
• Regenerative Medicine and Biomarkers for Dilated Cardiomyopathy

  2019cites this paper
• Association between elevated adiponectin level and adverse outcomes in patients with heart failure: a systematic review and meta-analysis

  2019cites this paper
• Drugs’ development in acute heart failure: what went wrong?

  2018cites this paper
• Bio-width index: a novel biomarker for prognostication of long term outcomes in patients with anaemia and heart failure

  2018cites this paper
• Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients

  2018influential citation
• Diagnosis and Treatment of Heart Failure for Inpatient Providers

  2018cites this paper
• Predictors of early and delayed recovery in peripartum cardiomyopathy: a prospective study of 52 Patients

  2018influential citation
• Serum Irisin Predicts Mortality Risk in Acute Heart Failure Patients

  2017cites this paper
• YiQiFuMai Powder Injection attenuates coronary artery ligation-induced myocardial remodeling and heart failure through modulating MAPKs signaling pathway.

  2017cites this paper
• Long-term serial kinetics of N-terminal pro B-type natriuretic peptide and carbohydrate antigen 125 for mortality risk prediction following acute heart failure

  2017cites this paper
• Monitoring Acute Myocardial Infarction Complicated with Cardiogenic Shock — from the Emergency Room to Coronary Care Units

  2017cites this paper
• Impact of CT-apelin and NT-proBNP on identifying non-responders to cardiac resynchronization therapy

  2017cites this paper
• Characteristics and outcomes of acute heart failure in sub Saharan Africa

  2016cites this paper
• [Biomarkers and clinical practice].

  2016cites this paper
• Comments on the 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure.

  2016cites this paper
• Pharmacogenomics in Drug Discovery, Prospects and Clinical Applicability

  2016cites this paper
• Natriuretic Peptides: Consensus Call for Use.

  2016cites this paper
• Treatment of Heart Failure With Reduced Ejection Fraction—Recent Developments

  2016cites this paper
• S100A1 as a Potential Diagnostic Biomarker for Assessing Cardiotoxicity and Implications for the Chemotherapy of Certain Cancers

  2015cites this paper
• Biomarcadores en la insuficiencia cardiaca aguda

  2015cites this paper
• ОЦІНКА ВІДДАЛЕНИХ НЕСПРИЯТЛИВИХ СЕРЦЕВО-СУДИННИХ ПОДІЙ У

  year unknowncites this paper